Biomarker Conference Boston 2027

Who sponsors ImmunoMark

Built for companies that sell to oncology R&D teams

Our London 2026 sponsors came from five kinds of company, and the Biomarkers & CDx stream adds a sixth. If yours is on this list, the agenda is built around your buyers.

Biomarker and lab services

Biomarker testing, flow cytometry and assay services for clinical trials.

Who you meet: Translational medicine and clinical biomarker leads

Preclinical models and discovery

In vivo models and antibody discovery for immuno-oncology pipelines.

Who you meet: Discovery, pharmacology and preclinical heads

Cell analysis and proteomics platforms

Instruments, reagents and platforms for immune profiling and proteomics.

Who you meet: Immune monitoring and translational science teams

Spatial biology and tissue analysis

Functional and spatial readouts from patient tissue.

Who you meet: Pathology and biomarker discovery leads

Research data and AI

Data, literature and analytics for R&D and competitive intelligence.

Who you meet: R&D strategy and data science teams

Diagnostics and CDx developers

The Biomarkers & CDx stream covers CDx development, regulatory strategy and market access.

Who you meet: Pharma CDx, regulatory and medical diagnostics leads

Stream 2: Biomarkers & Companion Diagnostics

Tell us which roles you need to meet and we will show you how the audience matches up.

Request the prospectus

Stream 2 in Boston

Why sponsor a biomarker conference in Boston in 2027

ImmunoMark Boston is a biomarker conference in Boston for the companies that make biomarker programs run: assay developers, platform companies, spatial and single-cell providers, multi-omics and bioinformatics teams, and biomarker lab services. The East Coast launch edition takes place in June 2027, with a full Stream 2 program on Biomarkers & Companion Diagnostics running alongside Stream 1, Immuno-Oncology.

The agenda describes Stream 2 as a focus on “biomarker discovery, validation, multi-omics technologies, companion diagnostic development, and the integration of biomarkers into clinical trials and precision medicine strategies”. For a vendor, that is close to a description of the buying journey: the same delegates who evaluate a new spatial or ctDNA method also decide whether it becomes a trial endpoint.

Boston is one of the best-known centers of translational oncology research in the world, with pharma R&D sites, biotech companies and academic cancer centers in close range. A launch edition here gives biomarker vendors an East Coast meeting point that is focused on oncology biomarkers rather than spread across every therapeutic area.

300+industry-focused delegates expected at the Boston launch edition

55–60%pharmaceutical and biotech companies in the agenda’s audience profile

45–50%senior leadership in the prospectus seniority profile

200+meetings held at London 2026

Technology to session map

Oncology biomarker conference sessions in Boston, matched to what you sell

Every row below is a real Boston session title. Use it to decide which day to staff hardest and which sessions to reference in your meeting requests.

If you sell	The Boston session that sets up your conversation
Spatial biology and multiplex imaging	Day 1 · Stream 2: The Spatial Path to Better Biomarkers (Emre Arslan, Associate Director, Takeda)
Liquid biopsy, ctDNA and methylation assays	Day 1 · Stream 2: Epigenetic Analysis in ctDNA; Day 2 · Stream 2: Biomarkers for Early Detection & MRD
Immune profiling and cell therapy analytics	Day 1 · Stream 2: Biomarker Assays, Immune Profiling, CAR-T, TCR-T, and NK Cell Therapies for Solid Tumors or Analytical Strategies Supporting Cell Therapies (Priyanka Joshi, Associate Scientist, Obsidian Therapeutics)
Biomarker lab services and clinical assay validation	Day 1 · Stream 2: Predictive & Prognostic Biomarkers in IO Trials; Translating Biomarkers into Clinical Endpoints
Multi-omics data, bioinformatics and AI	Day 2 · Stream 2: Bioinformatics & Data Integration
Commercial and value evidence	Day 1 · Stream 2: Panel Discussion: Commercialization of Biomarkers & CDx; Day 2 · Stream 2: Health Economics & Value of Biomarkers

Day 2 opens Stream 2 with Keynote: Biomarkers in FDA Oncology Approvals and closes with Future Trends in Biomarkers & CDx, so translational biomarker teams arrive with both the regulatory picture and the longer view in mind. That range is what makes this a translational biomarker conference rather than a discovery-only symposium.

Functions on the faculty

The biomarker functions on the Boston speaker panel

The Biomarker and Companion Diagnostics faculty reads like an org chart of the teams that buy assays, platforms and lab services. These are the functions in the room, not guaranteed meetings.

Clinical biomarker leads

Rachel Tam, Senior Principal Clinical Biomarker Scientist, Bristol Myers Squibb
Jinming “Jimmy” Xing, Associate Director, Clinical Biomarkers, Moderna

They decide which assays run in trials, and which lab runs them.

Pathology and translational science

Patrícia Coutinho de Souza, Associate Principal Scientist/Associate Director (R4) – Molecular Pathology, Merck
Sam Chatterjee, Translational scientist, Associate Director, AstraZeneca

They weigh tissue, imaging and molecular methods against sample limits and reproducibility.

Computational biology and diagnostics

Vinayagam Arunachalam, Senior Director, Head of Computational Biology and Digital | Early Development and Biomarkers, Takeda
Shantanu Shewale, Associate Director of Clinical Diagnostics, Regeneron

They own data integration and the step from biomarker to diagnostic.

Your 1:1 meetings are chosen from the full delegate list and profiles, sent about 10 days before the event, so you can target these functions across every company present, not only the speakers. For the wider picture of who is in the city and when, read our guide to Boston biotech and life sciences events.

Launch-edition advantage

How to run a biomarker summit in Boston in 2027 as a launch sponsor

Launch editions set the category positions buyers remember. A simple plan gets the most from the first East Coast edition.

Claim your Stream 2 slot earlyPlatinum, Gold and Silver sponsors choose their stream, and the agenda has three slots per tier per stream. The first spatial, ctDNA or multi-omics company in a slot sets the frame for the rest.
Build your meeting list from the delegate profilesFilter for clinical biomarker, translational medicine, molecular pathology and bioinformatics roles, and use the wishlist to flag your priority accounts.
Bring the scientist into the roomTwenty minutes is enough for one method and one dataset. When a clinical biomarker lead asks about sensitivity or sample volume, have the person who built the assay answer.
Use the eveningThe Day 1 drinks reception follows the commercialization panel, a natural moment to continue conversations about adoption and value.
Carry the visibility forwardEvery tier includes post-event branding on social media, the event website and the post-event report: the document future buyers read about the first Boston edition.

Work out your cost per qualified biomarker meeting with your own budget figures.

Run the ROI calculator

Package fit

Which packages fit assay, platform and biomarker lab service companies

Match the tier to the day your technology is discussed: Platinum talks run on Day 1, Gold talks on Day 2 before lunch.

Best fit

Platinum (Stream 2)

A Day 1 talk on the day the spatial, ctDNA, immune profiling and clinical endpoint sessions run, with meetings to follow up.

30-minute Day 1 talk plus Q&A in Stream 2
10 pre-scheduled 1:1 meetings
10 x 6 ft booth and a banner in the conference room
8 delegate + 8 client passes
Full-page brochure advertisement

Gold (Stream 2)

A Day 2 pre-lunch talk, on the morning the early detection and MRD session and the health economics session run.

30-minute Day 2 talk plus Q&A
6 pre-scheduled 1:1 meetings
10 x 6 ft booth
6 delegate + 6 client passes
Half-page brochure advertisement

Exhibitor

A booth presence for platform companies that demo better than they present.

10 x 6 ft exhibition area
2 delegate + 2 client passes
Wishlist and delegate list with contact details
Logo in the brochure and on the event website

Full details are on the Boston sponsorship opportunities page; the exclusive two-stream position is on the Boston headline sponsor page. If your buyers are CDx and regulatory teams, see the Boston companion diagnostics conference page; if you sell IO tools, the Boston immuno-oncology conference page. Comparing editions? Read the San Diego biomarker conference and London biomarker conference pages.

Tell us your technology and target functions and we will suggest a Stream 2 package.

Request the prospectus

Sponsorship ROI calculator

What could Boston 2027 be worth to your team?

Pick a package, add your own numbers and see the pipeline it creates. London 2026 sponsors averaged 15 to 25 meetings each, with 70% senior decision-makers in the room.

1. Choose a package

Sponsorship packages

Exclusive 1:1 meeting packages

2. Your numbers

Average first-year deal value

Year-one value of a new pharma or biotech customer

Extra conversations at the event

Booth visits, networking and questions after your talk

Become a real opportunity

Share of conversations worth a proposal

Opportunities you usually win

Your typical close rate

Your total event budget

Sponsorship plus travel and team costs

Estimated return

expected first-year revenue for every $1 of your event budget

Pre-scheduled 1:1 meetings

Qualified conversations

New opportunities

Cost per conversation

Pipeline created

Expected revenue won

Get pricing and the prospectus for this package

Talk to our team

Estimates only, based on the numbers you enter. Meetings and inclusions from the Boston 2027 sponsorship prospectus. 1:1 meetings are pre-scheduled with delegates you choose from the attendee list.

Email me this estimate

We will send your numbers to your inbox, ready to share with your team. Our sponsorship team gets a copy so they can answer questions.

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

Which Boston sessions matter most for a spatial or single-cell platform company?

On Day 1 of Stream 2, The Spatial Path to Better Biomarkers (Emre Arslan, Associate Director, Takeda) and Biomarker Assays, Immune Profiling, CAR-T, TCR-T, and NK Cell Therapies for Solid Tumors or Analytical Strategies Supporting Cell Therapies. On Day 2, Bioinformatics & Data Integration covers the multi-omics data side.

Is there content for liquid biopsy and MRD companies?

Yes. Day 1 of Stream 2 includes Epigenetic Analysis in ctDNA, and Day 2 includes Biomarkers for Early Detection & MRD. The Day 2 keynote is Biomarkers in FDA Oncology Approvals.

Who is in the audience?

The Boston agenda profiles the audience as 55–60% pharmaceutical and biotech companies, 10–15% academic and research institutions, 5–10% hospitals, cancer centers and CROs, and 5% government, regulatory and industry organizations. The prospectus expects 45–50% senior leadership.

Can we choose which delegates we meet?

Yes. You receive the full delegate list and profiles about 10 days before the event, choose who you want to meet and flag priorities with the wishlist feature. Meetings are 20 minutes and pre-scheduled. Headline, Platinum and Gold include meetings, and Exclusive 1:1 Meetings packages offer 3, 5, 7 or 10.

How does Boston compare with the San Diego and London biomarker editions?

All three run the same two-stream format and packages. San Diego (10–11 February 2027) and Boston (June 2027) are US launch editions on the West and East Coasts. London (3–4 March 2027) is the 2nd annual edition, with a UK and European delegate base and the 2026 edition as its track record.

Biomarker Conference Boston: Meet Clinical Biomarker Teams 1:1

Get the prospectus and package availability